Red dye No. 3 is now banned in the US. Here’s what studies show about more common dyes
Following the ban of red dye No. 3 in the United States, experts weigh in on the potential health risks of red dye No. 40, ...
JD Supra1d
FDA announces public meeting on pediatric exclusivity and drug development
Earlier this month, the U.S. Food and Drug Administration (FDA) announced a public meeting entitled “Interested Parties Meeting: Implementation of ...
Kennedy’s Plan for the Drug Crisis: A Network of ‘Healing Farms’
The positions of Robert F. Kennedy Jr. on vaccines and drug companies are well known. His approach to addiction has been far ...
FiercePharma2d
Government watchdog recommends tweaks to FDA accelerated approval program
The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...
Medpage Today on MSN2d
HHS Inspector General Raises Concerns Over FDA's Accelerated Approvals
Of the 24 drugs, three approvals deviated from the others -- aducanumab; the synthetic hormone hydroxyprogesterone caproate ...
Looking to the Future of the FDA and Its Impact on Drug Regulation in 2025
The authors write "The Food, Drug and Cosmetic Law Section of the New York State Bar Association is delving into the changing ...
BioPharma Dive3d
Federal watchdog cites concerns with FDA’s accelerated approval process
The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...
‘Drug drones’ being flown into prisons could be stopped by electronic forcefields
Drug drones being flown into prisons by organised crime gangs could be blocked by “electronic forcefields” that jam their ...
BioSpace3d
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...
Mena FN5d
Novamigra Tx Announces Successful Pre-IND Meeting With FDA, Paving The Way For Accelerated Clinical Development
(MENAFN- EIN Presswire) Novamigra Tx Announces Successful Pre-IND Meeting with FDA for Migraine Prophylaxis Asset VRG-145, Paving Way for Accelerated Clinical Development BUDAPEST, HUNGARY ...